Inhibition of FBP1 expression by KMT5A through TWIST1 methylation is one of the mechanisms leading to chemoresistance in breast cancer

Peng,Xue; Ma,Lisi; Chen,Xuan; Tang,Fen; Zong,Xiangyun

doi:10.3892/or.2024.8769

Inhibition of FBP1 expression by KMT5A through TWIST1 methylation is one of the mechanisms leading to chemoresistance in breast cancer

Authors:
- Xue Peng
- Lisi Ma
- Xuan Chen
- Fen Tang
- Xiangyun Zong
View Affiliations

Affiliations: Department of Breast Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, P.R. China
Published online on: July 3, 2024 https://doi.org/10.3892/or.2024.8769
Article Number: 110
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lysine methyltransferase 5A (KMT5A) is the sole mammalian enzyme known to catalyse the mono‑methylation of histone H4 lysine 20 and non‑histone proteins such as p53, which are involved in the occurrence and progression of numerous cancers. The present study aimed to determine the function of KMT5A in inducing docetaxel (DTX) resistance in patients with breast carcinoma by evaluating glucose metabolism and the underlying mechanism involved. The upregulation or downregulation of KMT5A‑related proteins was examined after KMT5A knockdown in breast cancer (BRCA) cells by Tandem Mass Tag proteomics. Through differential protein expression and pathway enrichment analysis, the upregulated key gluconeogenic enzyme fructose‑1,6‑bisphosphatase 1 (FBP1) was discovered. Loss of FBP1 expression is closely related to the development and prognosis of cancers. A dual‑luciferase reporter gene assay confirmed that KMT5A inhibited the expression of FBP1 and that overexpression of FBP1 could enhance the chemotherapeutic sensitivity to DTX through the suppression of KMT5A expression. The KMT5A inhibitor UNC0379 was used to verify that DTX resistance induced by KMT5A through the inhibition of FBP1 depended on the methylase activity of KMT5A. According to previous literature and interaction network structure, it was revealed that KMT5A acts on the transcription factor twist family BHLH transcription factor 1 (TWIST1). Then, it was verified that TWSIT1 promoted the expression of FBP1 by using a dual‑luciferase reporter gene experiment. KMT5A induces chemotherapy resistance in BRCA cells by promoting cell proliferation and glycolysis. After the knockdown of the KMT5A gene, the FBP1 related to glucose metabolism in BRCA was upregulated. KMT5A knockdown expression and FBP1 overexpression synergistically inhibit cell proliferation and block cells in the G2/M phase. KMT5A inhibits the expression of FBP1 by methylating TWIST1 and weakening its promotion of FBP1 transcription. In conclusion, KMT5A was shown to affect chemotherapy resistance by regulating the cell cycle and positively regulate glycolysis‑mediated chemotherapy resistance by inhibiting the transcription of FBP1 in collaboration with TWIST1. KMT5A may be a potential therapeutic target for chemotherapy resistance in BRCA.

View Figures

View References

1	Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436. 2022. View Article : Google Scholar : PubMed/NCBI
2	Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM and Goss PE: Breast cancer in China. Lancet Oncol. 15:E279–E289. 2014. View Article : Google Scholar : PubMed/NCBI
3	Vasan N, Baselga J and Hyman DM: A view on drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
4	Chen H, Zhang M and Deng Y: Long noncoding RNAs in Taxane resistance of breast cancer. Int J Mol Sci. 24:122532023. View Article : Google Scholar : PubMed/NCBI
5	Sajid A, Rahman H and Ambudkar SV: Advances in the structure, mechanism, and targeting of chemoresistance-linked ABC transporters. Nat Rev Cancer. 23:762–779. 2023. View Article : Google Scholar : PubMed/NCBI
6	Cao X, Hou J, An Q, Assaraf YG and Wang X: Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resist Updat. 49:1006712020. View Article : Google Scholar : PubMed/NCBI
7	Di Pietro A, Dayan G, Conseil G, Steinfels E, Krell T, Trompier D, Baubichon-Cortay H and Jault J: P-glycoprotein-mediated resistance to chemotherapy in cancer cells: Using recombinant cytosolic domains to establish structure-function relationships. Braz J Med Biol Res. 32:925–939. 1999. View Article : Google Scholar : PubMed/NCBI
8	Bukowski K, Kciuk M and Kontek R: Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 21:32332020. View Article : Google Scholar : PubMed/NCBI
9	Dominiak A, Chełstowska B, Olejarz W and Nowicka G: Communication in the cancer microenvironment as a target for therapeutic interventions. Cancers (Basel). 12:12322020. View Article : Google Scholar : PubMed/NCBI
10	Bishayee K, Lee SH and Park YS: The Illustration of altered glucose dependency in drug-resistant cancer cells. Int J Mol Sci. 24:139282023. View Article : Google Scholar : PubMed/NCBI
11	Xu L, Zhang L, Sun J, Hu X, Kalvakolanu DV, Ren H and Guo B: Roles for the methyltransferase SETD8 in DNA damage repair. Clin Epigenetics. 14:342022. View Article : Google Scholar : PubMed/NCBI
12	Al Temimi AHK, Martin M, Meng Q, Lenstra DC, Qian P, Guo H, Weinhold E and Mecinović J: Lysine Ethylation by histone lysine methyltransferases. Chembiochem. 21:392–400. 2020. View Article : Google Scholar : PubMed/NCBI
13	Kukita A, Sone K, Kaneko S, Kawakami E, Oki S, Kojima M, Wada M, Toyohara Y, Takahashi Y, Inoue F, et al: The Histone Methyltransferase SETD8 regulates the expression of tumor suppressor genes via H4K20 methylation and the p53 signalling pathway in endometrial cancer cells. Cancers (Basel). 14:53672022. View Article : Google Scholar : PubMed/NCBI
14	Wada M, Kukita A, Sone K, Hamamoto R, Kaneko S, Komatsu M, Takahashi Y, Inoue F, Kojima M, Honjoh H, et al: Epigenetic modifier SETD8 as a therapeutic target for high-grade serous ovarian cancer. Biomolecules. 10:16862020. View Article : Google Scholar : PubMed/NCBI
15	Liao T, Wang YJ, Hu JQ, Wang Y, Han LT, Ma B, Shi RL, Qu N, Wei WJ, Guan Q, et al: Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro. Oncol Rep. 39:2185–2192. 2018.PubMed/NCBI
16	Herviou L, Ovejero S, Izard F, Karmous-Gadacha O, Gourzones C, Bellanger C, De Smedt E, Ma A, Vincent L, Cartron G, et al: Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma. Clin Epigenetics. 13:1742021. View Article : Google Scholar : PubMed/NCBI
17	Li B, Qiu B, Lee DS, Walton ZE, Ochocki JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I and Simon MC: Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature. 513:251–255. 2014. View Article : Google Scholar : PubMed/NCBI
18	Li H, Li M, Pang Y, Liu F, Sheng D and Cheng X: Fructose-1,6-bisphosphatase-1 decrease may promote carcinogenesis and chemoresistance in cervical cancer. Mol Med Rep. 16:8563–8571. 2017. View Article : Google Scholar : PubMed/NCBI
19	Li H, Qi Z, Niu Y, Yang Y, Li M, Pang Y, Liu M, Cheng X, Xu M and Wang Z: FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signalling axis in ovarian cancer. Oncogene. 40:5938–5949. 2021. View Article : Google Scholar : PubMed/NCBI
20	Huang R, Yu Y, Zong X, Li X, Ma L and Zheng Q: Monomethyltransferase SETD8 regulates breast cancer metabolism via stabilizing hypoxia-inducible factor 1α. Cancer Lett. 390:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Thul PJ and Lindskog C: The human protein atlas: A spatial map of the human proteome. Protein Sci. 27:233–244. 2018. View Article : Google Scholar : PubMed/NCBI
23	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
24	Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER III, Barretina J, Gelfand ET, Bielski CM, Li H, et al: Next-generation characterization of the cancer cell line encyclopedia. Nature. 569:503–508. 2019. View Article : Google Scholar : PubMed/NCBI
25	Kenicer J, Spears M, Lyttle N, Taylor KJ, Liao L, Cunningham CA, Lambros M, MacKay A, Yao C, Reis-Filho J and Bartlett JM: Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance. BMC Cancer. 14:7622014. View Article : Google Scholar : PubMed/NCBI
26	Jørgensen S, Elvers I, Trelle MB, Menzel T, Eskildsen M, Jensen ON, Helleday T, Helin K and Sørensen CS: The histone methyltransferase SET8 is required for S-phase progression. J Cell Biol. 179:1337–1345. 2007. View Article : Google Scholar : PubMed/NCBI
27	Sousa-Pimenta M, Estevinho LM, Szopa A, Basit M, Khan K, Armaghan M, Ibrayeva M, Sönmez Gürer E, Calina D, Hano C and Sharifi-Rad J: Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: Paclitaxel, docetaxel, and cabazitaxel. Front Pharmacol. 14:11573062023. View Article : Google Scholar : PubMed/NCBI
28	Ma A, Yu W, Li F, Bleich RM, Herold JM, Butler KV, Norris JL, Korboukh V, Tripathy A, Janzen WP, et al: Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8. J Med Chem. 57:6822–6833. 2014. View Article : Google Scholar : PubMed/NCBI
29	Yang F, Sun L, Li Q, Han X, Lei L, Zhang H and Shang Y: SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 31:110–123. 2012. View Article : Google Scholar : PubMed/NCBI
30	Wang X, Cao C, Tan X, Liao X, Du X, Wang X, Liu T, Gong D, Hu Z and Tian X: SETD8, a frequently mutated gene in cervical cancer, enhances cisplatin sensitivity by impairing DNA repair. Cell Biosci. 13:1072023. View Article : Google Scholar : PubMed/NCBI
31	Phan LM, Yeung SC and Lee MH: Cancer metabolic reprogramming: Importance, main features, and potentials for precise targeted anticanceranti-cancer therapies. Cancer Biol Med. 11:1–19. 2014.PubMed/NCBI
32	Wang Y, Wang H, Ding Y, Li Y, Chen S, Zhang L, Wu H, Zhou J, Duan K, Wang W, et al: N-peptide of vMIP-II reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer. Int J Oncol. 51:918–930. 2017. View Article : Google Scholar : PubMed/NCBI
33	Yu B, Su J, Shi Q, Liu Q, Ma J, Ru G, Zhang L, Zhang J, Hu X and Tang J: KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling. Nature Commun. 13:21922022. View Article : Google Scholar : PubMed/NCBI